Literature DB >> 16518762

Liver-stage development of Plasmodium falciparum, in a humanized mouse model.

Serban Morosan1, Stéphanie Hez-Deroubaix, Francoise Lunel, Laurent Renia, Carlo Giannini, Nico Van Rooijen, Serena Battaglia, Catherine Blanc, Wijnand Eling, Robert Sauerwein, Laurent Hannoun, Jacques Belghiti, Christian Brechot, Dina Kremsdorf, Pierre Druilhe.   

Abstract

BACKGROUND: The liver stage of the human malaria parasite Plasmodium falciparum is the least known, yet it holds the greatest promise for the induction of sterile immunity and the development of novel drugs. Progress has been severely limited by the lack of adequate in vitro and in vivo models.
METHODS: Recently, it was found that immunodeficient mice transgenic for the urokinase plasminogen activator allow survival of differentiated human hepatocytes. We confirm this finding but show that hepatocyte survival is short lived unless nonadaptive defenses are simultaneously depleted.
RESULTS: By controlling macrophages and NK cells, we readily effected the long-term secretion of human serum albumin and human alpha-1 antitrypsin in mouse serum (at 3 months, the proportion of repopulated mice increased from 0% to 60% and from 22% to 80%, respectively; P<.0001). P. falciparum sporozoites delivered intravenously into mice readily infected transplanted human hepatocytes and developed into liver schizonts. Their size was twice as large as what was seen in vitro and was comparable to that found in humans and chimpanzees.
CONCLUSION: These results emphasize the importance of nonadaptive defenses against xenotransplantation and lead to development of small laboratory models that, because they can harbor human hepatocytes, provide novel opportunities to study intrahepatic pathogens, such as those causing malaria and hepatitis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16518762     DOI: 10.1086/500840

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  41 in total

1.  New horizons for studying human hepatotropic infections.

Authors:  Ype P de Jong; Charles M Rice; Alexander Ploss
Journal:  J Clin Invest       Date:  2010-02-22       Impact factor: 14.808

Review 2.  Live and let die: manipulation of host hepatocytes by exoerythrocytic Plasmodium parasites.

Authors:  Angelika Sturm; Volker Heussler
Journal:  Med Microbiol Immunol       Date:  2007-04-05       Impact factor: 3.402

Review 3.  A pre-emptive strike against malaria's stealthy hepatic forms.

Authors:  Dominique Mazier; Laurent Rénia; Georges Snounou
Journal:  Nat Rev Drug Discov       Date:  2009-11       Impact factor: 84.694

Review 4.  Current therapies and future possibilities for drug development against liver-stage malaria.

Authors:  Rene Raphemot; Dora Posfai; Emily R Derbyshire
Journal:  J Clin Invest       Date:  2016-06-01       Impact factor: 14.808

5.  Recapitulation of treatment response patterns in a novel humanized mouse model for chronic hepatitis B virus infection.

Authors:  Benjamin Y Winer; Tiffany Huang; Benjamin E Low; Cindy Avery; Mihai-Alexandru Pais; Gabriela Hrebikova; Evelyn Siu; Luis Chiriboga; Michael V Wiles; Alexander Ploss
Journal:  Virology       Date:  2016-12-19       Impact factor: 3.616

6.  Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection.

Authors:  Lander Foquet; Cornelus C Hermsen; Geert-Jan van Gemert; Eva Van Braeckel; Karin E Weening; Robert Sauerwein; Philip Meuleman; Geert Leroux-Roels
Journal:  J Clin Invest       Date:  2014-01       Impact factor: 14.808

7.  Cell therapy for the diseased liver: from stem cell biology to novel models for hepatotropic human pathogens.

Authors:  Nicolas Brezillon; Dina Kremsdorf; Mary C Weiss
Journal:  Dis Model Mech       Date:  2008 Sep-Oct       Impact factor: 5.758

8.  Repopulation efficiencies of adult hepatocytes, fetal liver progenitor cells, and embryonic stem cell-derived hepatic cells in albumin-promoter-enhancer urokinase-type plasminogen activator mice.

Authors:  Dhivya Haridass; Qinggong Yuan; Pablo D Becker; Tobias Cantz; Marcus Iken; Michael Rothe; Nidhi Narain; Michael Bock; Miriam Nörder; Nicolas Legrand; Heiner Wedemeyer; Kees Weijer; Hergen Spits; Michael P Manns; Jun Cai; Hongkui Deng; James P Di Santo; Carlos A Guzman; Michael Ott
Journal:  Am J Pathol       Date:  2009-08-28       Impact factor: 4.307

Review 9.  Plasmodium vivax: who cares?

Authors:  Mary R Galinski; John W Barnwell
Journal:  Malar J       Date:  2008-12-11       Impact factor: 2.979

Review 10.  Towards a small animal model for hepatitis C.

Authors:  Alexander Ploss; Charles M Rice
Journal:  EMBO Rep       Date:  2009-10-16       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.